Aethlon Medical (NASDAQ:AEMD) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Aethlon Medical (NASDAQ:AEMD) announced its earnings results on Wednesday. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09, Zacks reports.

Aethlon Medical Price Performance

Shares of NASDAQ AEMD traded down $0.01 during mid-day trading on Wednesday, reaching $0.67. The company’s stock had a trading volume of 557,624 shares, compared to its average volume of 1,213,018. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $1.85. The stock has a fifty day moving average of $0.62 and a two-hundred day moving average of $0.47. The firm has a market capitalization of $9.33 million, a PE ratio of -0.24 and a beta of 1.88.

Wall Street Analyst Weigh In

A number of analysts have commented on AEMD shares. StockNews.com began coverage on Aethlon Medical in a research report on Monday, January 27th. They issued a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research note on Thursday, January 30th.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.